A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910